Effect of stereoisomers related to ICRF-159 on metastasis of B16 melanoma

• Published in: British journal of cancer Vol. 44; no. 4; pp. 578 - 583
• Main Authors: Zwilling, B S, Campolito, L B, Reiches, N A, George, T, Witiak, D T
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.10.1981
• Subjects: Animals; Cell Division - drug effects; Cell Line; Cell Survival - drug effects; Lung Neoplasms - prevention & control; Lung Neoplasms - secondary; Male; Melanoma - drug therapy; Mice; Mice, Inbred C57BL; Neoplasms, Experimental - drug therapy; Piperazines - pharmacology; Razoxane - analogs & derivatives; Razoxane - pharmacology; Razoxane - therapeutic use; Stereoisomerism
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.1981.229

The antitumour effects of ICRF-159 and related analogues were evaluated using the B16 melanoma. Treatment of mice with ICRF-159 inhibited tumour growth, while each of the analogues, trans-4,4(1)-(1,2-cyclopropandiyl) bis (2,6-piperazinedione) (trans-5), and cis-4,4(1)-(1,2-cyclopropandiyl) bis (2,6-piperazinedione) (cis-7) independently accelerated primary tumour growth. Pretreatment of B16 melanoma cultures either with ICRF-159 or the analogue cis-7 decreased the yield of lung-colonies following i.v. injection of tumour cells. In contrast, pretreatment of tumour cells with the trans-5 analogue led to an increase in lung colonies. The effect on colony formation in vitro of these analogues correlated with increased growth in vivo, and not with lung colony formation.